Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUDARA vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
B-cell chronic lymphocytic leukemia (CLL) in adults who have not responded to or have progressed during treatment with at least one standard alkylating-agent regimen,Off-label: non-Hodgkin lymphoma, acute myeloid leukemia, conditioning for hematopoietic stem cell transplantation
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Fludarabine is dephosphorylated in serum to 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), which is then phosphorylated intracellularly to active triphosphate (F-ara-ATP). Further metabolism involves deamination by adenosine deaminase, but the primary route is renal excretion of unchanged drug and metabolites.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Fludarabine: 19-29% (primarily albumin); 2-fluoro-ara-A: minimal binding.
47% bound to human plasma proteins, primarily albumin.
Vd: 2.4 L/kg (fludarabine); 0.5-0.9 L/kg (2-fluoro-ara-A, approximating total body water).
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Oral: 55-75% under fasting conditions; food reduces Cmax but not AUC.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
Cr Cl 30-70 m L/min: reduce dose by 20%. Cr Cl <30 m L/min: contraindicated.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
No specific recommendations for hepatic impairment; use with caution in severe hepatic impairment (Child-Pugh C).
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Not established for pediatric patients; safety and efficacy not determined.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific adjustment; monitor renal function and hematologic parameters closely.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
WARNING: FLUDARA MAY CAUSE SEVERE BONE MARROW SUPPRESSION (ANEMIA, THROMBOCYTOPENIA, NEUTROPENIA) AND MAY INDUCE AUTOIMMUNE HEMOLYTIC ANEMIA. PATIENTS SHOULD BE MONITORED CLOSELY FOR HEMATOLOGIC TOXICITY. NEUROTOXICITY (INCLUDING BLINDNESS, COMA, AND DEATH) HAS BEEN REPORTED, PARTICULARLY AT HIGH DOSES (>40 mg/m2/day).
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Severe bone marrow suppression, particularly thrombocytopenia, anemia, and neutropenia,Autoimmune hemolytic anemia, which can be fatal,Neurotoxicity, especially at high doses; monitor for altered mental status, visual disturbances, seizures,Tumor lysis syndrome, especially in patients with high tumor burden,Immunosuppression and increased risk of opportunistic infections,Pulmonary toxicity including interstitial pneumonitis,Hepatotoxicity and increased liver enzymes,Use with caution in renal impairment; dose adjustment required (Cr Cl <30 m L/min)
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Hypersensitivity to fludarabine or any component of the formulation,Severe renal impairment (Cr Cl <30 m L/min) unless benefit outweighs risk,Pregnancy (can cause fetal harm),Lactation (discontinue nursing or drug)
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No specific dietary restrictions. Maintain adequate hydration. Grapefruit juice may interact; avoid excessive consumption. Avoid alcohol due to possible hepatotoxicity.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Fludarabine is contraindicated in pregnancy. It is a nucleoside analog with known teratogenic and embryotoxic effects. First trimester exposure is associated with major congenital malformations, particularly neural tube defects, craniofacial anomalies, and limb defects. Second and third trimester exposure can cause fetal growth restriction, myelosuppression, and increased risk of fetal death. Both animal studies and human case reports confirm significant fetal harm.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
No data exist on fludarabine excretion into human breast milk. Given its mechanism of action (DNA synthesis inhibitor) and potential for severe adverse effects (e.g., myelosuppression, carcinogenesis) in a nursing infant, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is unknown.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No established dose adjustments exist for fludarabine during pregnancy. Due to increased plasma volume, renal clearance, and altered pharmacokinetics in pregnancy, standard dosing may result in subtherapeutic levels. However, given the high teratogenic risk, use is contraindicated; if unavoidable (e.g., life-threatening maternal condition), consider therapeutic drug monitoring and dose individualization based on AUC, but data are extremely limited and safety cannot be assured.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
Fludarabine is a purine analog used in B-cell chronic lymphocytic leukemia (CLL). It requires dose adjustment in renal impairment (Cr Cl <30 m L/min). Myelosuppression is dose-limiting; monitor blood counts. Use with caution in patients with prior autoimmune hemolytic anemia. Trimethoprim-sulfamethoxazole should be given for Pneumocystis jirovecii prophylaxis. Allopurinol is recommended for tumor lysis syndrome prevention. Administer IV over 30 minutes or longer.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
Take this medication exactly as prescribed by your doctor.,You will need regular blood tests to monitor your blood cell counts.,Avoid live vaccines during treatment and for 12 months after.,Report any signs of infection (fever, chills, sore throat) or unusual bleeding/bruising immediately.,Use effective contraception during treatment and for at least 6 months after the last dose.,Drink plenty of fluids to help prevent kidney problems.,Avoid exposure to people with infections.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
"Roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor, enhances intracellular cyclic AMP levels, leading to suppression of pro-inflammatory cytokine production and modulation of immune cell function. Fludarabine, a purine analog used in hematologic malignancies, exerts immunosuppressive effects through inhibition of DNA synthesis and lymphocyte apoptosis. Concurrent use may result in additive or synergistic immunosuppression, increasing the risk of severe infections, including opportunistic infections, and potentially delaying immune recovery in patients already immunocompromised due to fludarabine therapy."
"The combination of tacrolimus and fludarabine may increase the risk of toxicity, particularly nephrotoxicity and neurotoxicity, due to additive immunosuppressive effects and potential pharmacokinetic interactions. Fludarabine may inhibit the metabolism of tacrolimus through CYP3A4 competition, leading to elevated tacrolimus levels and increased adverse effects, including renal impairment and neurological symptoms such as tremors and seizures. Close monitoring is required to avoid severe outcomes like opportunistic infections and organ damage."
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUDARA vs CLOLAR, answered by our medical review team.
FLUDARA is a Antineoplastic Agent that works by Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUDARA and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUDARA is: 25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUDARA and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUDARA is classified as Category C. Fludarabine is contraindicated in pregnancy. It is a nucleoside analog with known teratogenic and embryotoxic effects. First trimester exposure is associated with major congenital . CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.